Sanofi Chews The Fat: Rimonabant Anti-Obesity NDA To Be Filed By 2005
Executive Summary
Sanofi-Synthelabo expects to file an NDA for rimonabant in obesity by the first quarter of 2005, Exec VP-Scientific Affairs Gerard Le Fur told analysts during a business review in London Sept. 2
You may also be interested in...
Sanofi-Aventis Deal Means More Leverage With Managed Care
Sanofi's $65 bil. merger with Aventis will offer the combined entity additional negotiating clout with large U.S. drug purchasers, Exec VP-Operations Hanspeter Spek said during an April 26 conference call
Sanofi-Aventis Deal Means More Leverage With Managed Care
Sanofi's $65 bil. merger with Aventis will offer the combined entity additional negotiating clout with large U.S. drug purchasers, Exec VP-Operations Hanspeter Spek said during an April 26 conference call
Sanofi To Move Two NMEs Into Phase III In 2004, For Total Of Nine
Sanofi-Synthelabo plans to move two new molecular entities into Phase III during 2004